Afficher la notice abrégée

Evolution of patients with Sézary syndrome after mogamulizumab discontinuation for any cause except progression: a multicenter retrospective study (Moga-stop study)

dc.rights.licenseopenen_US
hal.structure.identifierHôpital Henri Mondor
dc.contributor.authorTZOUMPA, Sofia
hal.structure.identifierEpidemiology in Dermatology and Evaluation in Therapeutics [EpiDermE]
hal.structure.identifierHôpital Henri Mondor
dc.contributor.authorINGEN-HOUSZ-ORO, Saskia
hal.structure.identifierHopital Saint-Louis [AP-HP] [AP-HP]
hal.structure.identifierUniversité Paris Cité [UPCité]
dc.contributor.authorDE MASSON, Adèle
hal.structure.identifierBoRdeaux Institute in onCology [Inserm U1312 - BRIC]
hal.structure.identifierCentre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
dc.contributor.authorPHAM-LEDARD, Anne
hal.structure.identifierEpidemiology in Dermatology and Evaluation in Therapeutics [EpiDermE]
dc.contributor.authorEL AARBAOUI, Tarik
hal.structure.identifierCHU Montpellier = Montpellier University Hospital
dc.contributor.authorDEREURE, Olivier
hal.structure.identifierImmunology and New Concepts in ImmunoTherapy [INCIT]
hal.structure.identifierCentre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
hal.structure.identifierCentre d’Investigation Clinique de Nantes [CIC Nantes]
dc.contributor.authorQUEREUX, Gaëlle
hal.structure.identifierCentre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
dc.contributor.authorFAIZ, Sarah
hal.structure.identifierCentre Hospitalier Universitaire Brugmann [Bruxelles] [CHU]
hal.structure.identifierInstitut Jules Bordet [Bruxelles]
dc.contributor.authorDE VICQ DE CUMPTICH, Marine
hal.structure.identifierHopital Saint-Louis [AP-HP] [AP-HP]
hal.structure.identifierUniversité Paris Cité [UPCité]
dc.contributor.authorRAM-WOLFF, Caroline
hal.structure.identifierCHU Rouen
dc.contributor.authorJANELA-LAPERT, Raphaël
hal.structure.identifierUniversité de Lausanne = University of Lausanne [UNIL]
hal.structure.identifierCentre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne] [CHUV]
dc.contributor.authorGUENOVA, Emmanuella
hal.structure.identifierHôpital Cochin [AP-HP]
dc.contributor.authorLHEURE, Coralie
hal.structure.identifierCentre Hospitalier Universitaire d'Angers [CHU Angers]
dc.contributor.authorLE CORRE, Yannick
hal.structure.identifierCentre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
dc.contributor.authorADAMSKI, Henri
hal.structure.identifierUniversité de Lausanne = University of Lausanne [UNIL]
hal.structure.identifierGeneva University Hospitals and Geneva University
dc.contributor.authorBLANCHARD, Maël
hal.structure.identifierHôpital Nord [CHU - APHM]
dc.contributor.authorBONNET, Nathalie
hal.structure.identifierHôpital Nord [CHU - APHM]
dc.contributor.authorAMATORE, Florent
hal.structure.identifierCentre hospitalier de Valence
dc.contributor.authorGRANGE, Florent
hal.structure.identifierCentre Hospitalier Universitaire de Nice [CHU Nice]
dc.contributor.authorTROIN, Laura
hal.structure.identifierHopital Saint-Louis [AP-HP] [AP-HP]
hal.structure.identifierUniversité Paris Cité [UPCité]
dc.contributor.authorBAGOT, Martine
hal.structure.identifierBoRdeaux Institute in onCology [Inserm U1312 - BRIC]
hal.structure.identifierCentre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
dc.contributor.authorBEYLOT-BARRY, Marie
dc.date.accessioned2025-06-13T09:27:26Z
dc.date.available2025-06-13T09:27:26Z
dc.date.issued2024-04-25
dc.identifier.issn0007-0963en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/206902
dc.description.abstractEnThe results of this study suggest that a progressive discontinuation of mogamulizumab should be considered once response is obtained in Sezary syndrome patients, even after a treatment of short-duration. This may possibly minimize the risk of adverse effects, costs, and resistance to mogamulizumab. Additionally, our study emphasizes that mogamulizumab rechallenge should be encouraged as first-choice for relapsing patients.
dc.language.isoENen_US
dc.title.enEvolution of patients with Sézary syndrome after mogamulizumab discontinuation for any cause except progression: a multicenter retrospective study (Moga-stop study)
dc.typeArticle de revueen_US
dc.identifier.doi10.1093/bjd/ljae153en_US
dc.subject.halSciences du Vivant [q-bio]en_US
bordeaux.journalBritish Journal of Dermatologyen_US
bordeaux.pageljae153en_US
bordeaux.hal.laboratoriesBRIC (Bordeaux of Institute of Oncology) - U1312en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcehal
hal.identifierinserm-04559196
hal.version1
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exportfalse
workflow.import.sourcehal
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=British%20Journal%20of%20Dermatology&rft.date=2024-04-25&rft.spage=ljae153&rft.epage=ljae153&rft.eissn=0007-0963&rft.issn=0007-0963&rft.au=TZOUMPA,%20Sofia&INGEN-HOUSZ-ORO,%20Saskia&DE%20MASSON,%20Ad%C3%A8le&PHAM-LEDARD,%20Anne&EL%20AARBAOUI,%20Tarik&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée